Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse

D. A. Goodwin, C. F. Meares, M. J. McCall, M. K. Haseman, M. McTigue, C. I. Diamanti, W. Chaovapong

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.

Original languageEnglish (US)
Pages (from-to)493-502
Number of pages10
JournalJournal of Nuclear Medicine
Volume26
Issue number5
StatePublished - 1985
Externally publishedYes

Fingerprint

Monoclonal Antibodies
Lymph Nodes
Spleen
B-Cell Leukemia
Lymphatic Metastasis
Yttrium
Histocompatibility
Isoantigens
Inbred C3H Mouse
B-Cell Lymphoma
Subcutaneous Injections
Edetic Acid
Citric Acid
B-Lymphocytes
Metals
Lymphocytes
Ions
Antigens
Neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Goodwin, D. A., Meares, C. F., McCall, M. J., Haseman, M. K., McTigue, M., Diamanti, C. I., & Chaovapong, W. (1985). Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. Journal of Nuclear Medicine, 26(5), 493-502.

Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. / Goodwin, D. A.; Meares, C. F.; McCall, M. J.; Haseman, M. K.; McTigue, M.; Diamanti, C. I.; Chaovapong, W.

In: Journal of Nuclear Medicine, Vol. 26, No. 5, 1985, p. 493-502.

Research output: Contribution to journalArticle

Goodwin, DA, Meares, CF, McCall, MJ, Haseman, MK, McTigue, M, Diamanti, CI & Chaovapong, W 1985, 'Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse', Journal of Nuclear Medicine, vol. 26, no. 5, pp. 493-502.
Goodwin DA, Meares CF, McCall MJ, Haseman MK, McTigue M, Diamanti CI et al. Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. Journal of Nuclear Medicine. 1985;26(5):493-502.
Goodwin, D. A. ; Meares, C. F. ; McCall, M. J. ; Haseman, M. K. ; McTigue, M. ; Diamanti, C. I. ; Chaovapong, W. / Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse. In: Journal of Nuclear Medicine. 1985 ; Vol. 26, No. 5. pp. 493-502.
@article{22f735259cdd4cc581e0c749811e0c76,
title = "Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse",
abstract = "Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95{\%}, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.",
author = "Goodwin, {D. A.} and Meares, {C. F.} and McCall, {M. J.} and Haseman, {M. K.} and M. McTigue and Diamanti, {C. I.} and W. Chaovapong",
year = "1985",
language = "English (US)",
volume = "26",
pages = "493--502",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "5",

}

TY - JOUR

T1 - Chelate conjugates of monoclonal antibodies for imaging lymphoid structures in the mouse

AU - Goodwin, D. A.

AU - Meares, C. F.

AU - McCall, M. J.

AU - Haseman, M. K.

AU - McTigue, M.

AU - Diamanti, C. I.

AU - Chaovapong, W.

PY - 1985

Y1 - 1985

N2 - Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.

AB - Radiolabeling of a mouse monoclonal antibody (MoAb) specific for the mouse histocompatibility alloantigen IA(k) expressed by the B lymphocytes of BALB/k and C3H mice but not BALB/c mice was performed by mixing the chelate-labeled anti (α) IA(k) MoAb with purified, no-carrier-added 111In citrate. Labeling efficiency was 85-95%, and the labeled αIA(k) MoAb retained its antigen binding properties in vitro and in vivo. The organ, spleen, and lymph node distribution of intravenously and subcutaneously administered 111InαIA(k) MoAb was compared in mice, two IA(k) positive and one Ia(k) negative strains, and to 125IαIA(k) MoAb in one IA(k) positive strain. The 111InαIA(k) MoAb was more stable in vivo compared to 125IαIA(k) MoAb, as shown by a much slower excretion and a higher absolute uptake in lymph nodes and spleen. Lymph node to blood ratio was increased twofold by intravenous anti-EDTA MoAb. Subcutaneous injection permitted clear images of the tiny lymph nodes in the mouse. Potential clinical applications of 111Inα lymphocyte MoAb include localization of normal lymph nodes and T & B cell leukemias and lymphomas, as well as detecting lymphatic metastases of other cancers. Therapy may also be possible using MoAbs labeled with beta-emitting metal ions such as yttrium-90.

UR - http://www.scopus.com/inward/record.url?scp=0022404004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022404004&partnerID=8YFLogxK

M3 - Article

C2 - 3921673

AN - SCOPUS:0022404004

VL - 26

SP - 493

EP - 502

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 5

ER -